Last updated: March 10, 2026
What Is the Current Market Position of NDC 00078-0249?
NDC 00078-0249 refers to Remicade (infliximab), a monoclonal antibody biologic used to treat autoimmune conditions, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. As a biosimilar of Johnson & Johnson’s original product, Remicade, it benefits from a mature market with significant patent expirations enabling biosimilar competition.
Market Size and Adoption
- The global biologics market was valued at approximately $300 billion in 2022, with infliximab accounting for a sizable segment [[1]].
- Remicade's estimated sales in 2022 surpassed $7 billion, with the United States contributing roughly 50% of global revenue [[2]].
- Biosimilars of infliximab, starting from 2016 in the U.S., have captured around 40% of the infliximab market by 2022 [[3]].
Key Competitors
- Inflectra (Pfizer/Celltrion)
- Renflexis (Samsung Bioepis)
- Avsola (Amgen)
- Zessly (Sandoz)
Market penetration varies based on region, formulary access, and payer preferences.
What Are the Regulatory and Patent Landscapes?
- FDA approval for infliximab biosimilars was granted in 2016.
- Patent exclusivity for the original Remicade expired in 2018 in the U.S., enabling biosimilar entry.
- Patent litigation and exclusivity filings continue to influence market dynamics through 2024.
What Are the Price Trends and Projections?
Current Pricing
| Product |
Approximate Price Per Vial (U.S.) |
Notes |
| Remicade |
$2,500 - $3,000 |
List price; actual prices vary with discounts and rebates |
| Biosimilars |
$1,200 - $2,000 |
Price is approximately 40-50% lower than reference product |
Historical Pricing Trends
- Biosimilar prices entered the U.S. market at roughly 60-70% of the originator price.
- Price reductions for biosimilars have plateaued at around 50-60% discount over the past three years.
Projected Price Trajectory (Next 3-5 Years)
- Market Saturation Effect: As biosimilar market share approaches 75% by 2024, prices are expected to stabilize.
- Pricing Pressure: Under increased competition, biosimilar prices are forecasted to decline by an average of 10% annually through 2028, reaching an estimated $900-$1,100 per vial.
- Reimbursement Policies: Payer rebates and formulary prioritization could push net prices even lower, especially in managed care settings.
What Are the Key Market Drivers?
- Expiration of patents in major markets.
- Increasing acceptance among physicians and payers.
- Cost-containment efforts leading to preference for biosimilars.
- Regulatory pathways facilitating biosimilar approvals, with biosimilar-specific guidelines issued by agencies such as FDA.
What Challenges Could Impact Pricing and Market Share?
- Brand loyalty toward originator.
- Payer hesitancy due to concerns over interchangeability.
- Manufacturing complexities of biosimilars affecting supply and pricing.
- Regulatory hurdles in some markets, delaying penetration.
Summary of Key Data Points
| Aspect |
Data Point |
| Global biologic market |
$300 billion (2022) |
| Remicade revenue |
$7 billion (2022) |
| Biosimilar market share |
~40% (2022) |
| Biosimilar price range |
$1,200 - $2,000 per vial |
| Price decline forecast |
10% annually through 2028 |
Key Takeaways
- The infliximab market is mature with ongoing biosimilar competition.
- Price reductions have plateaued but remain significant.
- Market share is shifting towards biosimilars, pressuring originator prices.
- Cost and reimbursement policies heavily influence price trajectories.
- Further patent litigation and regulatory changes could modify market dynamics.
FAQs
1. What regions show the fastest adoption of infliximab biosimilars?
Europe leads with widespread biosimilar approval and adoption since 2016, followed by the U.S. post-2018 patent expiry.
2. How does biosimilar pricing compare to the original product?
Biosimilars currently sell at roughly 55-70% of the originator’s list price.
3. Will prices for infliximab biosimilars decrease further?
Yes. The trend suggests a 10% annual decline through 2028, driven by increased competition.
4. How do rebate and discount practices affect net prices?
Rebates can reduce net prices by 20-30%, especially in payers with strong negotiating positions.
5. What is the forecast for biosimilar market penetration?
Biosimilars are projected to reach about 75% market share of infliximab by 2024 in the U.S. and Europe.
References
[1] IQVIA. (2022). Global Biologics Market Report.
[2] EvaluatePharma. (2023). 2022 Biologics Sales Data.
[3] IMPACT Therapeutics. (2022). Biosimilar Market Penetration and Trends.
